A mutation in the IGFBP7 gene is associated with a very rare phenomenon in which people with amyotrophic lateral sclerosis (ALS) have a reversal in disease progression and experience partial or full recovery, a new study reports. Because the mutation results in less production of the resulting protein IGFBP7,…
News
A man with amyotrophic lateral sclerosis (ALS) implanted with Synchron‘s brain-computer interface was the first person in the world to use his thoughts to control an Apple Vision Pro. Using the investigational brain-computer interface, or BCI, the 64-year-old man, who’d lost function in his upper limbs due to ALS,…
A decade later, the family of Pete Frates, the amyotrophic lateral sclerosis (ALS) patient who helped start the Ice Bucket Challenge, is relaunching the campaign that went viral on social media, raising awareness and money to support ALS research. In an event organized by the Peter Frates…
The biotechnology company Revir Therapeutics has raised $30 million in funding to advance the development of oral genetic therapies for amyotrophic lateral sclerosis (ALS) and other neurodegenerative disorders. This Series A financing was led by the healthcare-focused venture capital firm Lapam Capital. Revir will use the proceeds to…
The investigational therapy BIIB078 was generally well tolerated in a Phase 1 clinical trial, but did not show evidence of slowing disease progression in people with amyotrophic lateral sclerosis (ALS) caused by mutations in the C9orf72 gene, according to recently published data from the trial. Because the trial failed to…
Treatment with Qalsody (tofersen) substantially slowed disease progression and reduced markers of nerve damage in people with amyotrophic lateral sclerosis (ALS) associated with SOD1 mutations (SOD1-ALS) who took part in an expanded access program in Germany. Patient-reported outcome measures also suggested a favorable perception of Qalsody, with most…
Nearly a year of treatment with TPN-101, an investigational oral molecule from Transposon Therapeutics, safely slowed disease progression and lung function decline in people with amyotrophic lateral sclerosis (ALS) related to C9orf72 mutations. That’s according to final data from a Phase 2a study (NCT04993755) that tested TPN-101…
A computer analysis using real-world data from an amyotrophic lateral sclerosis (ALS) clinic identified four groups of patients with distinct rates of disease progression, a new study by researchers in Portugal reported. The findings continue to demonstrate the differences in ALS presentation and progression seen among people with the…
Treatment with a high dose of ILB, an experimental injection therapy being developed by Tikomed, was well tolerated and appeared to slow the progression of amyotrophic lateral sclerosis (ALS) in a small clinical trial in the U.K. That’s according to data from the exploratory Phase 2 study…
A new genetic mutation that may cause amyotrophic lateral sclerosis (ALS) has been discovered in families living in La Rioja, a region in Spain, according to a study. The gene mutation, found in 10 ALS patients from seven different families, affected the ARPP21 gene, which encodes a protein that…
Recent Posts
- ‘Early birds’ have significantly lower ALS risk than ‘night owls’: Study
- As my late husband’s ALS progressed, we kept our bucket list simple
- Tossing and turning over fears this ALS journey has come to its end
- Experimental ALS therapy QRL-201 shows potential to slow disease decline
- Worried about an inability to multitask? Here’s what helped me.